Patent Application
Docket No. SPO-116
Serial No. 10/070,569

DT07 Rec'd PCT/PTO

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Takashi Muramatsu, Kohji Okamoto, Shinya Ikematsu, Munehiro Oda,

Hideshi Kumai, Sadatoshi Sakuma

Serial No.

10/070,569

Conf. No.

7190

Filed

March 8, 2002

For

Early Cancer Tumor Marker

Office of Initial Patent Examination Customer Service Center Commissioner of Patents and Trademarks Washington, D.C. 20231

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The applicants respectfully request the correction of an error in the official Filing Receipt for the above-identified patent application. The typographical error has occurred in spelling of the 6th inventors first name. The correction needed is as follows:

Applicant(s)

Sadotoshi Sakuma

should read

Sadatoshi Sakuma

A copy of the erroneous Official Filing Receipt accompanies this Request. Also, attached is a copy of page 1 of the Transmittal Letter Form PTO-1390 and a copy of the executed Declaration and Power of Attorney form. Correction of the above is respectfully requested.

Respectfully submitted,

David Saliwanchik

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.:

352-375-8100

Address:

2421 N.W. 41st Street, Suite A-1


Gainesville, FL 32606-6669

DRS/la

Enclosures: Copy of erroneous Filing Receipt;

Page 1 of Form PTO-1390;

Copy of Declaration and Power of Attorney form.





Commissioner for Patents Washington; DC 2023; www.uspto.gov

APPLICATION NUMBER

FILING DATE

GRP ART UNIT | FIL FEE REC'D

FEE REC'D ATTY.DOCKET.NO

DRAWINGS

TOT CLAIMS

IND CLAIMS

10/070,569

07/16/2002

1632

594

SPO-116


-12

9

5

23557
SALIWANCHIK LLOYD & SALIWANC
A PROFESSIONAL ASSOCIATION
2421 N.W. 41ST STREET

2421 N.W. 41ST STREET SUITE A-1 GAINESVILLE, FL 326066669



CONFIRMATION NO. 7190

FILING RECEIPT

OC000000009072570

Date Mailed: 11/07/2002

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Takashi Muramatsu, Aichi, JAPAN; Kohji Okamoto, Fukuoka, JAPAN; Shinya Ikematsu, Kanagawa, JAPAN; Munehiro Oda, Kanagawa, JAPAN; Hideshi Kumai, Kanagawa, JAPAN; Sadotoshi Sakuma, Tokyo, JAPAN;

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP00/06147 09/08/2000

Foreign Applications

JAPAN 11-256678 09/10/1999 JAPAN 11-345404 12/03/1999 JAPAN 2000-033168 02/10/2000

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

Title

Early cancer tumor marker

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

THE STANDARD TO BE WHEN A PARTY OF AN ARROWS HERE

Control of SUCOND of SURSEQUENCE of the control of the second of the control of t

with the artist of seventers that it

and (21) indicator (efort.

A Michigan Inc. 2 of the Property

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive management, and the same property of the same property

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Eoreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

化设计器 建头面的 医海绵性病

susband dulta said from the state.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		SPO-116	
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5	
CONCERNING A FILE	LING UNDER 35 U.S.C. 371		
TERNATIONAL APPLICATION NO		PRIORITY DATE OF A DATE	
PCT/JP00/06147	į	PRIORITY DATE CLAIMED	
TITLE OF INVENTION	08 September 2000	10 September 1999	
EARLY CANCER TUMOR MARKER			
APPLICANT(S) FOR DO/EO/US			
Takashi Muramatsu, Kohii Okamoto, Shinya Ikematsu, Munehiro Oda, Hitteshi Kumai, Sadatoshi Sakuma			
Applicant herewith submits to the United States Designated/Elected Office (DO/EQ/US) the following items and other information:			
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.			
4. The US has been elected by the expiration of 19 months from the priority date (Article 31).			
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
is attached hereto (required only if not communicated by the International Bureau).			
has been communicated by the International Bureau. The has been communicated by the International Bureau.			
c. is not required, as the application was filed in the United States Receiving Office (RO/US).			
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).			
a. is attached hereto.			
b. has been previously submitted under 35 U.S.C. 154(d)(4).			
7. Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3))			
a. are attached hereto (required only if not communicated by the International Bureau).			
b. have been communicated by the International Bureau.			
c. have not been made; however, the time limit for making such amendments has NOT expired.			
The standard of the have not been made and will not be made, as a standard of the arms of the standard of the			
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).			
9. An oath of declaration of the inventor(s) (35.U.S.C. 371(c)(4)) unsigned			
10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11 to 20 below concern document(s) or information included:			
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
3. A FIRST preliminary amendment.			
14. A SECOND or SUBSEQUEN			
15. A substitute specification.	A substitute specification.		
6. A change of power of attorney and/or address letter.			
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.			
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).			
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).			
20. Other items or information:	Certificate of Mailing by Express Mail		